CAR T-cell therapy and CRISPR-Cas9 gene editing enabled new directions for synthetic biology, and some researchers are using so-called synbio tools to develop tests and vaccines for COVID-19, according to Imperial College London chemical engineering lecturer Francesca Ceroni. She describes how bacterial and mammalian approaches to synbio can be leveraged for biomedical and bioproduction processes, and highlights some interesting research in the space.
How synthetic biology is advancing drug development
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.